MDLN Medline Inc
$36.47
▼ 0.3%Updated Oct 16, 2:25 PM ET
Report Card
MDLN at a glance — five pillars scored 0–100 from real filed financials.
How the 0–100 rating is calculatedOverall: not rated yet. This stock's fundamentals ratios aren't loaded, so only the pillars its filings support are scored.
Key Metrics
Market Cap
—
P/E
—
Forward P/E (est.)
—
ROE
—
Revenue Growth
—
EPS Growth
—
Profit Margin
—
FCF Yield
—
Debt / Equity
—
ROIC
7.0%
Interest Coverage
—
Current Ratio
4.33x
Dividend Yield
—
Implied Growth (rev. DCF)
—
Rating Score
Not rated
Business Overview
Medline Inc (MDLN) is a NASDAQ-listed company in the Health Care industry, within the Health Care sector.
In its latest reported year it generated about $28.43B in revenue and $1.16B in net profit.
Our model hasn't rated MDLN yet because its fundamentals ratios (P/E, margins, returns on capital, leverage) aren't loaded. Any financial history below comes straight from its SEC filings and refreshes automatically.
Revenue Growth
2Y CAGR
10.6%
Revenue moved from $23.23B in 2023 to $28.43B in 2025, a 10.6% compound annual growth rate. The most recent year was roughly steady year over year. Slower, mature growth is common for established businesses.
Profitability
Gross Margin
26.4%
Operating Margin
7.8%
Net Margin
4.1%
ROE
—
Debt Analysis
Total Debt
$12.58B
Net Debt
$10.25B
Net Debt / EBITDA
4.63x
Debt / Equity
—
Leverage: debt-to-equity is n/a, with a current ratio of 4.3x. Detailed balance-sheet leverage is limited for this name. It carries roughly $12.58B of total debt against $2.33B of cash.
Cash Flow Analysis
Operating CF
$1.74B
Free Cash Flow
$1.30B
FCF Margin
4.6%
In the latest year Medline Inc produced about $1.74B of operating cash flow and $1.30B of free cash flow after capital spending. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
Valuation Analysis
P/E
—
P/S
—
P/B
—
EV / EBITDA
—
MDLN trades at n/a trailing earnings. Its valuation ratios aren't loaded yet, so there is no P/E to judge here.
DCF Fair Value (Educational)
A two-stage discounted cash flow on real SEC-filed free cash flow — the intrinsic-value anchor professional analysts triangulate from.
How this DCF estimate is calculatedDCF fair value / share
—
Current price
$36.47
Starting FCF (latest 10-K)
$1.30B
Growth, years 1–5
4.0%
Fade to terminal, years 6–10
2.5%
Discount rate
9.0%
Cash flows grow at the stage-1 rate (trailing revenue growth, capped at 20%) for five years, fade to 2.5% by year 10, and continue at that rate forever (Gordon terminal value), all discounted at 9.0%. Small changes in assumptions move the result a lot — treat this as one reference point, not a target price. Educational only, not investment advice.
Metrics vs. Sector Range
Where MDLN sits versus the Health Care companies we cover.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in our coverage that have fundamentals data — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
Sector Peer Comparison
How MDLN stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
MDLN doesn't have a model rating yet (its fundamentals ratios aren't loaded), so it isn't ranked against the 83 rated Health Care companies we cover.
P/E vs sector
—
median 26.1x
ROE vs sector
—
median 14.1%
Growth vs sector
—
median 7.6%
Sector rank
—
not rated yet
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size, preferring ones with full data. Sector medians and rank use the 83 rated companies among the 324 Health Care stocks we cover. Educational, not a recommendation.
Key Risks
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
Latest SEC Filings
MDLN's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen. How to read a 10-K
MDLN — frequently asked questions
Is MDLN a good stock to buy?
We don't give buy or sell advice. Review Medline Inc's fundamentals, valuation, and 5-year financials on this page, then make your own decision — and consider a licensed professional.
Where does MDLN's data come from?
Live price data plus the annual financials in Medline Inc's SEC filings, refreshed automatically. Its fundamentals ratios aren't loaded yet, which is why it has no model rating.
How is the 5-year projection for MDLN calculated?
It's a scenario model. It starts from the latest annual revenue and net margin in SEC filings, grows revenue at an assumed rate (trailing revenue growth by default), and applies a P/E range built around today's multiple to show the resulting share-price range. When a stock has no growth or P/E data, the starting values are placeholders. It's a tool for thinking, not a prediction.
Is this MDLN analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell MDLN. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.